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Background: Although the diagnosis of subdural hematoma is usually straightforward,
occasionally it may be erroneous, leading to mistakes in the treatment. For example,
leptomeningeal malignancies, even in the absence of bleeding, may clinically and radiolog-
ically mimic subdural hemorrhage.
Objective: To stress the importance of not only intuitive thinking but also in analytic thinking
in appropriate and accurate treatment strategies.
Methods and Illustrative case: In this report, the clinical and radiological pitfalls in differenti-
ating malignant leptomeningeal inﬁltration and subdural hematomas are discussed. A
sample case of an intracranial extra-osseous manifestation of a multiple myeloma that
is atypical with regard to its location and clinical presentation is presented for illustration.
Conclusions: The variability of intracranial presentation and the wide spectrum of leptome-
ningeal malignancies necessitate careful preoperative evaluation of the patient's individual
history as well as radiological images to avoid misdiagnosis. A clinician who has become
familiar with the pitfalls in the differential diagnosis between leptomeningeal inﬁltrations
and subdural hematoma will act more analytically to solve the patient's problems properly
and avoid potential complications for the patient.
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Subdural hematomas are frequently considered as neurosur-
gical emergency cases [1]. Although the diagnosis of subdural
hematoma is usually straightforward, occasionally it may be
erroneous, leading to ﬂawed treatment. For example, lepto-
meningeal malignancies, even in the absence of bleeding, may
clinically and radiologically mimic subdural hemorrhage of
any stage, such as acute, subacute or chronic [2–5]. The
misinterpretation of morphological-neuroimaging features
can lead to inappropriate surgical decision-making and
consequently to a suboptimal neurosurgical and oncological
approach. In cases of acute subdural hematoma, urgent
surgery is the treatment of choice, whereas in cases of
leptomeningeal neoplastic inﬁltration with subdural tumor
progression in patients with extensive cancer, the same
strategy may worsen the course of the disease [6]. Moreover,
urgent implementation of the oncological therapy may thus be
delayed. Furthermore, in the surgery of chronic subdural
hematoma, one or two burr holes and the drainage of blood
may be adequate, whereas, in cases of tumoral lesions the aim
would either be a large craniotomy, intra-operative biopsy and
frozen section examination of the biopsy specimen and gross
total removal of the tumor or a biopsy alone, depending on the
underlying pathology.
Intracranial manifestation of a multiple myeloma is very
rare and represents less than 1% of all intracranial tumors [7,8].
Because of the aggressiveness and invasiveness of myeloma
cells, intracranial involvement may be dural, leptomeningeal
or intraparenchymal, or manifest in skull bone, as well as in
cranial nerve lesions [2–5,8–11]. Leptomeningeal and dura
mater involvement in multiple myeloma is estimated to be
even more rare [3,12,13]. Extra-osseous neoplastic hemispher-
ic intracranial lesions may be confused with a subdural
hematoma, especially in a computed tomography (CT) image,
in which the hypercellularity of the lesion may appear as a
hyperdense, crescent-shape, extra-axial collection and thus
imitate an acute hemorrhage [2,14].
In this report, clinical and radiological pitfalls in differenti-
ating malignant leptomeningeal inﬁltration and subdural
hematomas are discussed. A sample case of an intracranial
extra-osseous manifestation of a multiple myeloma that is
atypical with regard to its location and clinical presentation is
presented for illustration.
2. Illustrative case
A 62-year old woman was diagnosed with a multiple myeloma
IgG, type Lambda, Durie–Salmon, Stage II, four years ago.
Initially, the manifestations of the disease were multiple
osteolytic lesions in the vertebrae. In the course of the disease,
an extra-osseous progression appeared and one year later
switched to the stage III. After a chemotherapy regime,
including lenalidomide, pomalidomide, and ﬁnally autologous
stem cell transplantation, partial remission of the disease was
achieved. The further course of the disease was interpreted as
stable. One year later there was a relapse of the disease, and
consequently a multimodal oncological approach with re-induction therapy including lenalidomide, bendamustin,
pomalidomide and skeletal radiation was implemented.
Six months later, the patient was admitted into hospital
because of a general weakness, somnolence, and a novel
moderate, left-sided hemiparesis. Glasgow Coma Scale (GCS)
score of the patient was 11 (eye opening to speech 3, verbal
response with inappropriate words 3, best motor response;
localizing pain, 5).
A CT scan showed a right-sided, extra-axial, hemispherical,
hyperdense lesion with a secondary mass effect displacing the
gray-white matter interface medially, and midline shift (Fig. 1),
which was interpreted as an acute subdural hematoma.
Additionally, a preoperative laboratory examination showed
pancytopenia with a low thrombocytes level. Because of the
clinical symptoms and the radiological signiﬁcant mass effect
of the extra-axial lesion, the decision to perform an emergency
evacuation was made.
Intraoperative features of intracranial presentation of multiple
myeloma. Intraoperatively, unexpectedly, instead of a hemato-
ma, tumor tissue was found. A frozen section was possible
during emergency surgery, and was made but the ﬁnal results
of examination were not waited, because the main aim of the
operation was to remove the mass lesion, decompress the
cerebral tissue and avoid herniation. The initial craniotomy
had to be enlarged with the aim of complete tumor resection.
The tumor mass appeared smooth, lobulated and well
vascularized. Invasion of the calvarium appeared as an
irregular erosive, osteolytic destruction. The inﬁltrated dura
was hypervascularised, thickened and inseparable from an
inﬁltrated arachnoidea. Consequently, a subdural space did
not exist, being broadly ﬁlled by an inﬁltrative tumor process.
Microscopically, the intradural mass, inﬁltrating the arachnoi-
dea and pia, complicated the plane dissection, separation and
removal of the tumor without causing damage to the
superﬁcial cortical neurovascular layer. Even minimal manip-
ulations resulted in bleeding from the fragile pathological
neoplastic neo-vessels of the pia and cortical superﬁcial micro-
vessels leading to cortical micro-contusions. Despite this, the
lesion could be removed near gross totally.
Histopathological examination proved the lesion to be an
intracranial manifestation of multiple myeloma (Fig. 2).
Microscopically, there were ﬁbrovascular septae throughout
the tumor mass, variable tumor-cells, cells with eccentrically
shaped large nucleoli, a high mitotic rate and additionally,
apoptotic cells. Immunohistochemically, the tumor cells
showed a markedly positive CD 138 proﬁle. There was no
reaction using the CD20 antibody. Sporadic kappa–light chains
and a signiﬁcantly high level of positive lambda chains were
seen. The proliferation rate (Ki67) was 80–90%.
Postoperatively, the immediate clinical condition of the
patient was satisfactory. She recovered complete conscious-
ness. Postoperatively, GCS score of the patient was 15 (eye
opening; spontaneous 4, verbal response; orientated 5, best
motor response; obeying commands 6, apart from hemipar-
esis). The left sided hemiparesis improved markedly. Oncol-
ogical therapy and radiotherapy of the cranium was indicated
because of achieving subtotal tumor resection, and begun
immediately after the wound healed. Unfortunately, the
radiotherapy had to be interrupted because of impairment
to the wound healing. Simultaneously, the patient developed a
Fig. 1 – (A) Pre-operative axial, non-contrast CT (soft tissue window) demonstrates a right-sided fronto-parietal, slightly
hyperdense subdural collection of plasma cell myeloma, initially thought to be an acute subdural hematoma. (B) Coronal
view showing the same subdural lesion with secondary mass effect. A midline shift is also seen.
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suppressed immune system. Although intensive, antiviral
therapy and supportive care were implemented, the patient's
condition worsened rapidly. Two months after neurosurgical
intervention the patient died.
3. Discussion
3.1. Clinical differential features between intracranial
multiple myeloma and subdural hematoma
A careful and detailed evaluation of the patient's history, the
course of disease and its dynamics, is crucial and mandatory
for accurate image interpretation and appropriate treatment
strategy. Clinical history, symptoms and signs may be
misleading in the differential diagnosis between subdural
hematoma and leptomeningeal malignant lesions. Leptome-
ningeal malignant inﬁltrations are mainly seen in advanced
stages of the cancers of the prostate, breast and lung, in
sarcomas and in hematologic malignancies such as multiple
myeloma and lymphomas [2,5,15–25] (Table 1). Previous to
intracranial involvement and its clinical manifestation, there
is usually a prolonged history over several years of the primary
malignant lesion solely. Nevertheless, a sporadic primary
intracranial involvement as a ﬁrst manifestation without
peripheral manifestation of the tumor lesion has been
reported in the literature [26].
In the case of intracranial metastatic involvement, the
spread of tumor cells is possible by many paths, including thehematogenous route, breaking through the blood-brain-barri-
er, or directly from adjacent tissues, or ﬁnally, via cerebrospi-
nal ﬂuid space, by diffuse circulating myeloma cells [14].
However, there may be no history of malignancy and
leptomeningeal inﬁltration during the initial presentation of
the disease [26]. Furthermore, if the patient develops some
focal neurological deﬁcits and there is a history of falls or head
trauma, a speculative and inaccurate diagnosis of intracranial
bleeding can easily be made. Finally, a patient with diagnosed
intracranial leptomeningeal involvement may simultaneously
develop a subdural hemorrhage independently after a trau-
matic episode [27]. Moreover, this group of cancer patients
seems to be more predisposed to develop of subdural
hemorrhage because of the fragility of the neo-vasculature
of the inﬁltrated leptomeningeal layer. Additional factors
leading to increased tendency of bleeding in the presence of
multiple myeloma, such as interference of myeloma-produced
antibodies against clotting factors, or amyloid damage of the
endothelium and platelet dysfunction certainly may play a
signiﬁcant role in the imbalance of hematological homeostasis
[39]. However, the deﬁnite mechanism of hematological
malignancies associated with intracranial hemorrhage has
not been clearly deﬁned and the exact mechanisms of these
coincidence are still under investigation [27].
In the preoperative stage of clinical decision-making, the
dynamics of developing clinical symptoms should be carefully
evaluated. Clinical ﬁndings of acute SDH can vary from none to
severe neurological deﬁcits including coma. Most patients
with acute SDH rapidly develop consciousness deterioration
and are low on the Glasgow Coma Scale on admission.
Fig. 2 – Histopathological (A), Immunohistochemical analysis (B, C, D) and features of the tumor. (A) HE; tumor mass with large
neoplastic cells with large oval and eccentric lied nuclei divided by delicate fibrovascular septae (B) CD 138 is diffusely
expressed in the cell membrane of the tumor cells, (C) Lambda-light chain is prominently expressed, (D) The proliferation
rate (Ki67), is estimated to be approximately 80–90%.
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anticoagulated patients is common [28]. Acute subdural
hemorrhage with or without leptomeningeal neoplastic
involvement develops rapidly in most cases and through
constantly increasing mass effect leads to life-threatening
brain herniation, clinically manifesting as progressiveTable 1 – A literature review regarding errors in treatment ass
hematoma and leptomeningeal tumoral lesions.
Author Year Pathology 
Oertel [19] 2003 Spindle cell sarcoma 
Schluterman [5] 2004 Multiple myeloma 
Evliyaoglu [25] 2006 Non-Hodgkin's lymphoma 
Tsang [20] 2006 Multiple myeloma 
Yoon [18] 2008 Non-Hodgkin's lymphoma 
Cheng [21] 2009 Metastatic adenocarcinoma of the pros
Ramnarayan [24] 2013 Non-Hodgkin's lymphoma 
Mathon [22] 2013 Burkitt lymphoma 
Boukas [15] 2015 Metastatic adenocarcinoma of the pros
Nzokou [17] 2015 Metastatic adenocarcinoma of the prosneurological deﬁcits with anisocoria and unconsciousness
[29]. In these cases, the classical emergency neurosurgical
approach aims at the volumetric reduction of the hematoma
and thus a decrease in intracranial pressure as the treatment
of choice. Additionally, clinical diagnosis may be complicated
by nonspeciﬁc neurological and vegetative symptoms, such asociated with the differential diagnosis between subdural
Errors
Twist drill craniostomy
Preoperative misdiagnosis, possible mistake in surgery
Inadequate bony exposure at the beginning of surgery
Bur hole, possible delay in CT and RT
Bur hole in the beginning of surgery
tate Inadequate bony exposure at surgery
Two operations, no biopsy in the ﬁrst one
Surgical technique: Bur hole
tate Repeated bur hole drainage, biopsy in the second surgery
tate Surgical technique: Bur hole, no frozen section
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 1 ( 2 0 1 7 ) 2 5 2 – 2 5 8256headache, vomiting, nausea and lethargy, which may indicate
an increased intracranial pressure related to rapidly increasing
mass effects in acute subdural hematomas. However, these
symptoms are often observed in leptomeningeal carcinoma-
tosis without a mass effect [30]. Moreover, metabolic side
effects of multiple myeloma even without intracranial
manifestation may lead to neurological deterioration; atten-
dant hypercalcemia may produce lethargy, weakness or
confusion. Hyperviscosity of blood intensiﬁes headache and
fatigue, leads to visual disturbance and causes retinopathy
[31]. Summarizing, there are no absolute pathognomonic,
characteristic clinical symptoms neither for a SDH, nor for
intracranial and leptomeningeal myeloma involvement,
which are sufﬁcient and infallible at the stage of clinical
diagnostic decision making.
From a biological and hematooncological point of view, the
multiple myeloma represents a malignant proliferation of
plasma cells derived from a single clone and belongs to a group
of B-cell lymphoproliferative diseases [31,32]. Multiple myelo-
ma is a neoplasm of a single clone of well-differentiated
plasma cells. It is characterized by a proliferation of plasma
cells in the bone marrow, predominantly involving the ribs,
sternum, spine, skull and proximal extremities, and the
inﬁltration of adjacent tissues by mature and immature
plasma cells [33]. In contrast, a plasmocytoma is a solitary
neoplasm of monoclonal plasma cells. In the course of tumoral
activity and biological behavior, a plasmocytoma may prog-
ress to its disseminated, malignant form, namely multiple
myeloma [11]. Although the initial predilection is involvement
of spinal vertebrae, osseous lesions in the skull base, nose, and
paranasal sinuses are reported [26,28]. The latter is thought to
be a strong positive predictor for progression from solitary
plasmocytoma to multiple myeloma.
The intracranial presentation of a multiple myeloma has a
wide variety of imaging manifestations, ranging from lesions
with an extra-axial, focal or diffuse meningeal enhancement
to solid or diffuse intra-axial, intraparenchymal nodules or
masses mimicking other intracranial tumors [7,28,34]. Intra-
cranial involvement and unusual locations for example, skull
base involvement with myelomatous inﬁltration and second-
ary hypoglossal nerve palsy has been described previously
[9,11,28,35–37]. Other unusual locations, such as the involve-
ment of the orbit, cavernous sinus, Meckel's cave, sella turcica,
petrous bone or clivus have also been reported [26,28,38,39].
Some rare presentations, such as myelomatous meningitis
with diffuse meningeal thickening, may exist with intrapar-
enchymal lesions [10].
Intracranial progression of tumor masses can be a result of
the invasion of tumor cells arising from the calvaria or the
skull base [14]. Since the dura mater is relatively avascular,
dural involvement is believed to be a consequence of direct
spread of the involved bone lesion. On the other hand, primary
dural involvement is extremely rare [3,12,13]. Leptomeningeal
spread can occur hematogenously as focal, multifocal or
diffuse [14]. Roddie and co-workers studied myelomatous
involvement of the dura mater in patients with multiple
myeloma [3]. In samples taken in autopsy, in patients with
leptomeningeal involvement, they found circulating myeloma
cells which diffusely inﬁltrated arachnoid veins, consequently
leading to the destruction and occlusion of arachnoidtrabeculae. Through this path, further spread into the
cerebrospinal ﬂuid may be possible.
3.2. Radiological differential features of intracranial
multiple myeloma and subdural hematoma
Apart from the patient's history and clinical examinations,
radiological studies may also be misleading. If clinical ﬁndings
lead to a diagnosis of an intracranial hematoma, then the
routinely preferred radiological examination is usually a non-
contrast CT scan solely [32]. Even in patients with a history of
cancer, additional neuro-imaging modalities are usually not
ordered in urgent cases with a subdural lesion diagnosed by
the initial CT scan. On the other hand, the preferred
radiological examination in cases with an intracranial tumoral
lesion is magnetic resonance imaging (MRI) with and without
contrast medium administration. Leptomeningeal tumor
inﬁltrations can be seen as hyperdense lesions in CT scans,
even without any obvious bleeding [5,14].
Radiologically, intracranial multiple myeloma can present
in various forms; from a solid and well-limited lesion to diffuse
inﬁltrating mass lesions [14,28,40]. From a radiological point of
view, the CT depicts lesions that involve cortical bone, and
appear as well deﬁned lytic, destructive and erosive lesions
without a sclerotic border, involving the diploe and cortical
bone. The extra-axial mass generally respects the border of
brain tissue. MRI shows extra-osseous, intracranial involve-
ment. Typically, the lesions appear isodense to hyperdense on
CT, isointense to hyperintense on T1-weighted MRI and
markedly hypointense on T2-weighted MRI. Notably, hyper-
density on CT modality as well as a hyperintensity on T1-
weighted MRI suggest a high cellularity and a low nucleo-
cytoplasmic ratio. Because of dense vascularity, after admin-
istration of contrast media the lesion is markedly enhanced.
The multiple myeloma shows increased diffusion-weighted
images [23]. If surgery for an intracranial multiple myeloma is
intended it is important to perform both non-contrast CT and
MRI with and without contrast medium administration
preoperatively, the former to delineate osseous involvement
and the latter to demonstrate the soft tissue, myelomatous
involvement of meninges or brain parenchyma.
3.3. How to provide individual treatment
The treatment strategies for multiple myeloma in patients
with systemic manifestation are clearly deﬁned [31]. In
contrast, there is a lack of guidelines for the treatment of
progressed stages of multiple myeloma with intracranial
involvement.
From the hemato-oncological point of view, multiple
myeloma in its phase of disseminated malignancy of plasma
cells represents the ﬁnal stage of the disease progression
[26,39]. The stage of the disease involving dural and leptome-
ningeal compartments correlates with a very poor prognosis
and should be considered a distinct complication of myeloma
disease [3]. This is of critical importance in preoperative
treatment strategy decision-making. As in the case presented
here, the extremely poor prognosis of patients with myeloma-
tous involvement of the meninges is estimated to be on
average approximately eight weeks from the onset of
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in our opinion, it is essential that neurosurgical intervention
and neurosurgical treatment regimens in the extensive stage
of multiple myeloma with intracranial involvement should be
individually indicated. In cases of suspected subdural hema-
tomas in patients with diagnosed multiple myeloma, where
possible, a preoperative MRI scan should be performed to
differentiate the tumor mass from the hematoma. In emer-
gency cases with a computer tomogram diagnosed life-
threatening mass effect of intracranial lesion, an emergency
craniotomy with aim of reducing the mass effect and
evacuating the lesion should be performed. On the other
hand, for patients with intracranial involvement, who are
neurologically stable, apart from detailed focused on intracra-
nial and neuroaxis MRI ﬁndings, an immunohistochemical,
morphological, cytogenetic proﬁle of the myeloma should be
evaluated and systemic co-morbidities taken into account,
with aim of implementing an individual therapy. Various
multimodal treatments options for intracranial myelomatous
involvement have been proposed, including cranial radiother-
apy, intrathecal chemotherapy and systemic chemotherapy,
but in general responses are partial and short-lived [3].
4. Conclusion
The consequences of erroneous diagnosis can be fatal.
Unnecessary surgery may worsen the prognosis of patients
with a leptomeningeal malignant lesion without any intracra-
nial bleeding, during the ﬁnal stage of the disease. The
variability of intracranial presentation and the wide spectrum
of leptomeningeal malignancies, varying from focal to diffuse,
from extra-axial to intra-axial, from cranial osseous to
meningeal and intraparenchymal, necessitate careful preop-
erative evaluation of the patient's individual history as well as
of radiological images to avoid misdiagnosis. A neurosurgeon
or a trauma surgeon should be very cautious in the diagnosis of
subdural hematoma in patients with extensive cancer disease
in order to avoid unexpected surgical and prognostic compli-
cations. A clinician who has become familiar with the pitfalls
in the differential diagnosis between leptomeningeal inﬁltra-
tions and subdural hematoma will employ analytical thought
processes to provide appropriate treatment.
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